Kexing Biopharm Co., Ltd.
Clinical trials sponsored by Kexing Biopharm Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company developing vaccines and biological products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Inhaled interferon could be new weapon against severe RSV in young children
Disease control Recruiting nowThis phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improveme…
Phase: PHASE3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New growth hormone treatment for short children enters final testing phase
Disease control Recruiting nowThis study tests a new growth hormone injection (GB06) in 192 children aged 3 to 11 with growth hormone deficiency, a condition that causes slow growth. The treatment is given daily for 52 weeks to see if it helps children grow taller at a similar rate to an existing approved hor…
Phase: PHASE3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shot aims to reverse cancer wasting
Symptom relief Recruiting nowThis early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…
Phase: PHASE1 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC